-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QK3YSN7DOkY3Kf8HO1qymU4wvhauq0gfdUGsNO6ISRrp1sLt+uumzm2hehaHLa/9 flEsFg2tWSK1L39iOP62lg== 0001362310-07-000054.txt : 20070124 0001362310-07-000054.hdr.sgml : 20070124 20070124060105 ACCESSION NUMBER: 0001362310-07-000054 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070119 ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant FILED AS OF DATE: 20070124 DATE AS OF CHANGE: 20070124 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NORTHWEST BIOTHERAPEUTICS INC CENTRAL INDEX KEY: 0001072379 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943306718 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-33393 FILM NUMBER: 07548072 BUSINESS ADDRESS: STREET 1: 18701 120TH AVENUE NE STREET 2: SUITE 100 CITY: BOTHELL STATE: WA ZIP: 98011 BUSINESS PHONE: 4256083008 MAIL ADDRESS: STREET 1: 18701 120TH AVENUE NE STREET 2: SUITE 100 CITY: BOTHELL STATE: WA ZIP: 98011 8-K 1 c70166e8vk.htm FORM 8-K e8vk
Table of Contents

 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 19, 2007

 

NORTHWEST BIOTHERAPEUTICS, INC.
 (Exact name of registrant as specified in its charter)

 
         
DELAWARE   0-33393   94-3306718
(State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)
     
18701 120th Avenue NE, Suite 101, Bothell, WA
  98011
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (425) 608-3000
 
INAPPLICABLE
(Former name or former address if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

 

1

 

Table of Contents

ITEM 2.03 Creation of a Direct Financial Obligation.

On January 19, 2007, Northwest Biotherapeutics, Inc. (the “Company”) received a cash advance in the amount of $500,000 from Toucan Partners, LLC (“Toucan”). The Company and Toucan are presently negotiating the terms pursuant to which this cash advance will be required to be repaid.

 

 

3

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NORTHWEST BIOTHERAPEUTICS, INC.

By: /s/ Alton Boynton                         
Alton L. Boynton
President

January 24, 2007

 

 

4

-----END PRIVACY-ENHANCED MESSAGE-----